Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Silence Therapeutics (SLN) EPS (Basic) (2020 - 2025)

Historic EPS (Basic) for Silence Therapeutics (SLN) over the last 4 years, with Q3 2025 value amounting to -$0.15.

  • Silence Therapeutics' EPS (Basic) rose 4000.0% to -$0.15 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.45, marking a year-over-year increase of 176.8%. This contributed to the annual value of -$0.33 for FY2024, which is 1601.65% up from last year.
  • According to the latest figures from Q3 2025, Silence Therapeutics' EPS (Basic) is -$0.15, which was up 4000.0% from -$0.19 recorded in Q2 2025.
  • Silence Therapeutics' 5-year EPS (Basic) high stood at $0.09 for Q4 2024, and its period low was -$0.25 during Q3 2024.
  • In the last 4 years, Silence Therapeutics' EPS (Basic) had a median value of -$0.16 in 2022 and averaged -$0.13.
  • As far as peak fluctuations go, Silence Therapeutics' EPS (Basic) soared by 15311.43% in 2024, and later crashed by 90000.0% in 2025.
  • Silence Therapeutics' EPS (Basic) (Quarter) stood at -$0.16 in 2022, then dropped by 7.13% to -$0.17 in 2023, then soared by 153.11% to $0.09 in 2024, then tumbled by 269.18% to -$0.15 in 2025.
  • Its EPS (Basic) stands at -$0.15 for Q3 2025, versus -$0.19 for Q2 2025 and -$0.2 for Q1 2025.